TestDynamics

Vendor-neutral platform for evaluating, combining, and prioritizing medical imaging AI algorithms.

Website: https://testdynamics.net/

Cover Block

From the public record

Field Value
Name TestDynamics
Tagline Vendor-neutral platform for evaluating, combining, and prioritizing medical imaging AI algorithms. [Healthcare Innovation, November 2026]
Headquarters Austin, United States [Startup Nation Finder]
Founded 2021 [Startup Nation Finder]
Stage Series A [Healthcare Innovation, November 2026]
Business model SaaS
Industry Healthtech
Technology AI / Machine Learning
Geography North America
Growth profile Venture Scale
Founding team Solo Founder
Founder Lior Eshel, founder and CEO [Business Wire, November 2026]
Funding label Series A [Healthcare Innovation, November 2026]
Total disclosed funding Approximately $9,000,000, based on the disclosed Series A announced November 16, 2026 [Healthcare Innovation, November 2026]

Links

From the public record

The Short Version

PUBLIC TestDynamics builds a vendor-neutral software layer for medical imaging AI, and it merits investor attention now because it has paired a newly announced $9 million Series A with a thesis that many hospital systems will need an orchestration and evaluation layer rather than another standalone algorithm [Healthcare Innovation, November 2026] [Axios, November 2026] [Business Wire, November 2026]. The company was founded in 2021 in Austin, and public interviews indicate the origin story was personal: CEO and founder Lior Eshel has said the business was shaped by his father’s lung cancer misdiagnosis, a detail that helps explain the company’s focus on diagnostic workflow and clinical decision support rather than consumer-facing AI [FTS Podcast, October 2026] [greenlight.guru, 2024].

The core product, Satori, is described on the company website as a system that runs imaging AI as one program, while third-party and company-backed coverage describe it more specifically as a platform that evaluates, combines, and prioritizes outputs from multiple imaging AI tools inside existing radiology workflows [TestDynamics] [Healthcare Innovation, November 2026] [Business Wire, November 2026]. That positioning is the main differentiator in the public record: TestDynamics is not presented as a single-model developer, but as an independent layer for selection, benchmarking, governance, and workflow presentation across multiple vendors, a concept the company later branded as "Amalgamated Intelligence" in late 2025 [TestDynamics] [Business Wire, November 2025] [AuntMinnie].

The founding bench appears concentrated around Eshel. Publicly available sources consistently identify him as founder and CEO, but do not yet establish a broader named leadership team or a prior high-profile exit, so the team case rests more on category conviction and customer problem selection than on a deeply documented executive roster [Business Wire, November 2026] [Lior Eshel Ansher | LinkedIn] [Healthcare Innovation, November 2026].

On financing, the clearest public milestone is the November 2026 Series A: $9 million led by Healthier Capital with participation from Cedars-Sinai Technology Ventures, alongside references to earlier support from MATTER, the Cedars-Sinai Accelerator, SilverTech Ventures, and Project FinTech [Healthcare Innovation, November 2026] [Axios, November 2026] [Crunchbase]. The business model is presented as SaaS, and the buyer set implied by the website and coverage centers on hospitals, health systems, imaging centers, radiology groups, and the operational stakeholders responsible for deploying several AI tools across one imaging environment [TestDynamics] [Healthcare Innovation, November 2026].

Over the next 12 to 18 months, the public watchpoints are fairly plain. Investors will want evidence that vendor-neutral orchestration translates into repeatable multi-site deployments, clearer proof of clinical and operational outcomes, and broader adoption beyond the early institutional relationships highlighted in current coverage, especially as the company expands across additional imaging subspecialties using fresh Series A capital [Healthcare Innovation, November 2026] [Business Wire, November 2026].

Single-source, plausible -- Relies on multiple public sources for funding, company positioning, and founder identity, but several product and deployment details remain company-described or only partially corroborated.

Taxonomy Snapshot

Axis Value
Stage Series A
Business Model SaaS
Industry / Vertical Healthtech
Technology Type AI / Machine Learning
Geography North America
Growth Profile Venture Scale
Founding Team Solo Founder
Funding $9,000,000 disclosed

The Company in Brief

PUBLIC

TestDynamics presents as a young imaging AI infrastructure company rather than a point-solution algorithm vendor. The company was founded in 2021 and is headquartered in Austin, Texas, according to its Crunchbase profile, while its website centers the pitch on making imaging AI work through a platform called Satori that runs multiple imaging AI tools as one program [Crunchbase] [TestDynamics].

The public record is thin on legal-entity detail, but the operating story is reasonably clear from company-controlled materials. TestDynamics says Satori includes modules for algorithm selection, unified viewing, governance, expert program management, and onboarding, and frames its buyers as healthcare organizations, imaging leaders, radiologists, IT and informatics teams, hospitals and health systems, and imaging centers or radiology groups [TestDynamics]. That supports a reading of the business as enterprise SaaS for clinical imaging workflows, though the company website does not publicly provide state filing detail in the materials reviewed [TestDynamics].

The main dated milestone visible in public sources is the company’s November 2025 introduction of "Amalgamated Intelligence," which it described as a framework for unifying medical imaging AI into one system, followed by a disclosed $9 million Series A in November 2026 that Crunchbase lists on the company profile [Crunchbase] [TestDynamics] [Business Wire, November 2025]. In sequence, that suggests a company moving from category definition toward scaled commercial deployment, but the chronology beyond those milestones remains only partially documented in the sources permitted for this section [Crunchbase] [TestDynamics].

Single-source, plausible -- Grounded primarily in the company website and partially corroborated by Crunchbase; legal entity detail and fuller milestone history were not confirmed in the permitted sources.

What They Have Built

Mixed sourcing

The product story is fairly clear even where the technical claims are still mostly company-described. TestDynamics presents Satori as a vendor-neutral platform that lets health systems run multiple imaging AI tools through one operational layer, with modules for algorithm selection, result review, governance, and managed program support [TestDynamics]. The company website describes this in plain operational terms: "one agreement, one connection, one clear view," with product surfaces including Satori Catalogue, Satori View, Satori Governance, Satori Stewards, and Clear Start onboarding [TestDynamics].

Press coverage and company announcements frame the software as an orchestration and evaluation layer inside existing radiology workflows rather than a standalone diagnostic model [Healthcare Innovation, November 2026] [Business Wire, November 2026]. According to the November 2026 financing announcement, Satori benchmarks imaging algorithms and delivers a single prioritized result for radiologists, while the November 2025 category launch introduced "Amalgamated Intelligence" as TestDynamics' term for combining outputs from multiple imaging AI systems into one decision-support framework [Business Wire, November 2026] [Business Wire, November 2025]. Independent trade coverage broadly repeats that positioning, describing the approach as a unified view across multiple medical imaging AI tools, though the deeper claims around continuous benchmarking against clinical ground truth remain company-led and should be read that way [AuntMinnie] [g-medtech.com] [healthtechnologyinsights.com].

What is easier to verify than the model mechanics is the workflow intent. The homepage states that Satori is aimed at imaging leaders, radiologists, IT and informatics teams, hospitals and health systems, and imaging centers and radiology groups, which suggests the company is selling a cross-functional operating layer rather than a single-reader productivity app [TestDynamics]. Healthcare Innovation also reported that the platform's architecture is vendor-neutral and tied to an initial Cedars-Sinai deployment, which is directionally consistent with TestDynamics' claim that customers want one place to evaluate and manage multiple algorithms [Healthcare Innovation, November 2026]. The public record, however, does not provide a verified technical stack, published performance data, or a product demo detailed enough to assess implementation depth.

Unconfirmed -- Core product surfaces are confirmed on the company website, but several material capability claims remain company-led or lightly corroborated by trade press.

Market Size and Demand

PUBLIC

The market matters now because hospitals are no longer deciding whether to try imaging AI, they are deciding how to manage a growing number of tools without breaking radiology workflow or governance.

The evidence available here supports the orchestration problem more clearly than it supports a precise market size. No named third-party TAM, SAM, or SOM figure for TestDynamics' exact category, vendor-neutral imaging-AI orchestration, appears in the supplied public record. What is documented is the company's own framing that health systems need "one agreement, one connection, one clear view" to run imaging AI programs at scale, alongside product modules for algorithm selection, unified viewing, and governance [TestDynamics]. Independent coverage also describes Satori as a vendor-neutral platform for evaluating algorithms, benchmarking them, and presenting a prioritized output inside existing radiology workflows [Healthcare Innovation, November 2026] [Business Wire, November 2026]. That combination suggests TestDynamics is selling into an emerging software layer between imaging-AI point solutions and hospital IT, but the size of that layer cannot be quantified from the cited material alone.

Demand drivers are easier to observe than market size. The company's homepage and product descriptions point to a recurring operational burden for imaging leaders: selecting among multiple algorithms, proving them on local patient data, monitoring performance, and presenting results in one clinical view [TestDynamics] [Business Wire, November 2025]. Healthcare Innovation's November 2026 coverage reinforces the same need by describing the company as an imaging-AI orchestration platform and tying the new capital to broader hospital-system deployments and clinical validation [Healthcare Innovation, November 2026]. In plain terms, the tailwind is not simply more AI models entering radiology. It is the management overhead created when health systems adopt several of them at once.

Adjacent markets are clearer than the core market boundary. TestDynamics sits at the overlap of medical imaging AI, clinical decision support, and healthcare workflow software, with some governance functionality that begins to resemble enterprise software for model management [TestDynamics] [Business Wire, November 2025]. Substitute approaches likely include buying directly from a single imaging-AI vendor, relying on internal informatics teams to evaluate tools one by one, or using broader healthcare AI infrastructure products that can route or monitor algorithms even if they are not built around radiology-specific workflow. The supplied sources also name CARPL and Ferrum Health as competitors, which supports the view that this is a real, if still loosely defined, buying category rather than a purely self-described segment [Crunchbase] [F4].

Regulatory and macro forces cut in both directions. On the favorable side, the company's positioning around benchmarking against clinical ground truth, governance, and ongoing measurement maps to a healthcare environment that is generally moving toward tighter evidence requirements for AI in care delivery [Business Wire, November 2026] [Business Wire, November 2025]. On the constraining side, hospital software budgets, integration cycles, and validation requirements tend to stretch adoption timelines, especially for products touching diagnostic workflow. The fact pattern in the public record, including emphasis on clinical validation and large health-system deployments, implies that commercial traction in this segment is likely gated as much by implementation and proof obligations as by model performance alone [Healthcare Innovation, November 2026] [TestDynamics].

Market lens Public evidence What it suggests
Core category Vendor-neutral platform for evaluating, combining, and prioritizing imaging-AI outputs in radiology workflow [Healthcare Innovation, November 2026] [Business Wire, November 2026] An orchestration and decision-support layer, rather than a single-algorithm vendor
Buying center Imaging leaders, radiologists, IT and informatics, hospitals and health systems [TestDynamics] Multi-stakeholder enterprise sale inside provider organizations
Demand trigger Need to choose tools, prove them on patient data, and measure performance over time [TestDynamics] [Business Wire, November 2025] Governance and workflow complexity appear to be the commercial wedge
Adjacent markets Medical imaging AI, clinical decision support, healthcare workflow software [TestDynamics] [Business Wire, November 2025] The company benefits if spending expands across any of these connected budgets

The table shows a market defined more by workflow and governance pain than by a clean published TAM. That is typical for young infrastructure categories in healthcare, but it also means investors should treat category-size claims cautiously until third-party market data catches up.

Single-source, plausible -- Market framing is supported by company materials and independent coverage from Healthcare Innovation and Business Wire, but no named third-party market sizing report for this exact category appears in the public source set.

Who Else Is Fighting for This

MIXED TestDynamics is positioning itself less as a new imaging algorithm vendor than as the coordination layer that sits between hospitals and the growing set of point-solution radiology AI tools, which places it in a narrower but increasingly relevant lane than direct algorithm developers [TestDynamics] [Healthcare Innovation, November 2026] [Business Wire, November 2025].

Company Positioning Stage / Funding Notable Differentiator Source
TestDynamics Vendor-neutral platform for evaluating, combining, and prioritizing imaging AI outputs within existing radiology workflows Series A, $9M announced November 2026 Frames itself as an independent orchestration and benchmarking layer rather than a single-algorithm vendor [Healthcare Innovation, November 2026] [Business Wire, November 2026] [Business Wire, November 2025] [TestDynamics]
CARPL Imaging AI marketplace and orchestration platform for discovery, validation, and deployment of radiology AI applications Named competitor in structured research; funding details not used here Competes from the platform layer rather than from a single clinical model [Crunchbase, Unknown]
Ferrum Health Hospital-facing AI deployment infrastructure for running and monitoring clinical AI applications Named competitor in structured research; funding details not used here Stronger association with enterprise AI infrastructure and operational deployment inside health systems [Crunchbase, Unknown]

The table points to a small set of companies competing above the model layer. TestDynamics, CARPL, and Ferrum Health each appear to be selling a way for providers to operationalize multiple AI tools, but they approach the stack from slightly different directions according to the available public record [Healthcare Innovation, November 2026] [Business Wire, November 2025] [Crunchbase, Unknown]. TestDynamics emphasizes vendor neutrality, comparative evaluation, and a unified radiologist view, while Ferrum Health is better understood as infrastructure for health-system AI deployment, and CARPL has been described in market databases as a discovery and deployment platform for imaging AI applications [TestDynamics] [Healthcare Innovation, November 2026] [Crunchbase, Unknown]. Adjacent substitutes are not only these named challengers, but also the status quo: health systems buying one algorithm at a time from imaging AI vendors and stitching workflows together internally, or relying on PACS and radiology IT teams to manage fragmented deployments without a dedicated orchestration layer [Business Wire, November 2025] [Healthcare Innovation, November 2026].

TestDynamics' clearest edge today is conceptual and workflow-level rather than financial. Its public materials consistently describe Satori as a single program, one connection, and one clear view for multiple imaging AI tools, and outside coverage echoes that the product evaluates and prioritizes outputs from more than one algorithm inside existing clinical workflows [TestDynamics] [Healthcare Innovation, November 2026] [Business Wire, November 2026]. That matters because provider buyers often struggle less with finding an AI model than with comparing vendors, validating them on local data, and managing performance over time. If TestDynamics can remain the neutral scorekeeper, that position could become durable through workflow embedding and trust with hospital stakeholders. Still, the durability is not yet fully established in public evidence, because the same neutrality claim is also perishable: larger platforms can add benchmarking and governance features, and incumbent hospital IT relationships tend to favor vendors that already control deployment rails [Business Wire, November 2025] [TestDynamics].

The company's main exposure is that a coordination layer can be squeezed from both sides. Ferrum Health appears better placed if the buying center prioritizes enterprise infrastructure, governance, and system-wide AI operations over radiologist-facing prioritization alone [Crunchbase, Unknown]. CARPL, by contrast, is exposed to the same broad buyer problem as TestDynamics and may compete more directly where hospitals want a marketplace-style environment for evaluating and turning on multiple radiology applications [Crunchbase, Unknown]. TestDynamics also does not appear, from the public record provided here, to own a proprietary imaging algorithm franchise or a hospital distribution channel at national scale, which limits its ability to dictate standards if customers decide they prefer to consolidate with a platform that combines orchestration, deployment, and vendor procurement in one contract [Healthcare Innovation, November 2026] [Business Wire, November 2026].

The most plausible competitive scenario over the next 18 months is continued convergence around AI operations platforms for health systems rather than a winner-take-all outcome in radiology AI itself. TestDynamics is the likely winner if hospitals increasingly want a vendor-neutral adjudication layer and can point to dissatisfaction with managing overlapping algorithm vendors one by one, because that is the precise pain point the company has chosen to solve [TestDynamics] [Business Wire, November 2025]. Ferrum Health is the likely winner if procurement shifts toward broader enterprise AI infrastructure and health systems decide the control point should sit with deployment and governance rather than comparative prioritization at the reading workflow. In that same scenario, TestDynamics would be the most exposed loser if health systems conclude that orchestration features are useful but not distinct enough to warrant a separate platform budget [Healthcare Innovation, November 2026] [Crunchbase, Unknown].

Single-source, plausible -- Core positioning is corroborated by TestDynamics' website, Healthcare Innovation, and Business Wire, but competitor descriptions in this section rely partly on limited public database coverage rather than multiple independent operating-source disclosures.

Opportunity

PUBLIC

The prize here is unusually large if execution holds, because the company is not trying to sell one more imaging model, it is trying to become the operating layer hospitals use to evaluate, govern, and act on many models at once inside existing radiology workflows [TestDynamics] [Healthcare Innovation, November 2026] [Business Wire, November 2026].

The headline opportunity is to become the default orchestration and decision-support layer for medical imaging AI across health systems. That is a bigger outcome than being a single-application imaging vendor, because the public product record consistently points to a vendor-neutral control point: the homepage says Satori runs imaging AI as "one program" with "one agreement, one connection, one clear view," while Healthcare Innovation and Business Wire describe a platform that benchmarks algorithms, compares their outputs, and presents radiologists with a prioritized result inside existing workflows [TestDynamics] [Healthcare Innovation, November 2026] [Business Wire, November 2026]. That outcome is still early rather than proven, but it is reachable in public evidence because the company has raised a dedicated Series A, has strategic participation from Cedars-Sinai Technology Ventures, and has publicly tied the capital to clinical validation and broader hospital deployments rather than to a category reset that does not yet exist [Axios, November 2026] [Business Wire, November 2026] [Healthcare Innovation, November 2026].

The public paths to scale are narrower than a general AI platform story, but they are legible.

Scenario What happens Catalyst Why it's plausible
Health-system control plane TestDynamics becomes the layer a hospital uses to run multiple imaging AI tools under one operational framework, reducing procurement and workflow fragmentation Additional health-system deployments following the November 2026 Series A and the company's stated push for clinical validation [Healthcare Innovation, November 2026] [Business Wire, November 2026] The product is publicly positioned around unified operation, benchmarking, governance, and workflow integration rather than single-model output, which fits enterprise platform buying behavior in radiology [TestDynamics] [Business Wire, November 2025]
Independent evaluation standard Satori becomes the trusted external benchmark for choosing among competing imaging algorithms on local patient data Broader adoption of continuous benchmarking and governance modules such as Satori Catalogue and Satori Governance [TestDynamics] The wedge is explicit in public materials: TestDynamics frames model selection and measurement as an independent layer, and Business Wire's 2025 category launch centered on unifying fragmented imaging AI into one decision-support system [TestDynamics] [Business Wire, November 2025]
Strategic infrastructure partner The company becomes an attractive partner or acquisition target for major imaging, workflow, or health-system software players that need neutral orchestration rather than another point solution Proof of repeatable deployments at major medical centers and deeper strategic ties with institutions such as Cedars-Sinai [Healthcare Innovation, November 2026] [Business Wire, November 2026] Public reporting already shows strategic investor participation from Cedars-Sinai Technology Ventures and an initial Cedars-Sinai deployment referenced in coverage, which is often how infrastructure software earns credibility in clinical settings [Healthcare Innovation, November 2026] [Crunchbase]

The scenarios share a common pattern: the upside expands if buyers decide the real bottleneck is not model availability but model management. That is the narrow but credible opening in the current record.

Compounding, if it appears, would likely come from workflow embedment plus evidence accumulation. The homepage product stack points to several layers of stickiness, Catalogue for tool selection, View for unified findings, Governance for measuring algorithms against customer goals, and Stewards for expert program operation, all of which suggest a system that can widen after initial deployment rather than remain a single-feature install [TestDynamics]. If Satori is used first to evaluate algorithms on a hospital's own patient data, then to present consolidated results to radiologists, and then to govern performance over time, each added workflow increases the switching cost and improves the company's position in later buying cycles [TestDynamics] [Business Wire, November 2026]. Public reporting also says the company intends to use new funding for clinical validation and expansion into additional imaging subspecialties, which matters because each validated specialty could make the same platform more useful to the same account without requiring a new infrastructure sale [Healthcare Innovation, November 2026] [Business Wire, November 2026].

The size of the win is hard to anchor precisely because the public record here does not include revenue, deployment counts, or a named market-size study. Still, there is a realistic upper-end interpretation. If TestDynamics became a strategic infrastructure layer adopted across major health systems, the likely value would resemble high-value clinical workflow infrastructure rather than a narrow diagnostic application. With a disclosed $9 million Series A announced in November 2026, the company is still at an early capitalization stage, so even a later outcome as a strategic acquisition target for imaging or enterprise health IT could represent a materially larger enterprise than today (scenario, not a forecast) [Business Wire, November 2026] [Axios, November 2026]. The public evidence supports ambition, but not precision: the upside case rests on becoming the neutral system of record for how hospitals evaluate and operationalize many imaging algorithms, not on winning with one algorithm of its own [TestDynamics] [Healthcare Innovation, November 2026].

Single-source, plausible -- Core opportunity framing is supported by the company website, Healthcare Innovation, Business Wire, and Axios, but several operational claims remain company-described rather than independently quantified.

Sources

From the public record

  1. [Healthcare Innovation, November 2026] TestDynamics Lands $9 Million to Scale Imaging AI Orchestration Platform | https://www.hcinnovationgroup.com/imaging/artificial-intelligence/article/55419078/testdynamics-lands-9-million-to-scale-imaging-ai-orchestration-platform

  2. [Startup Nation Finder] TestDynamics - Israeli Startup | Startup Nation Finder | https://finder.startupnationcentral.org/company_page/testdynamics

  3. [Axios, November 2026] Exclusive: TestDynamics raises $9M to expand medical imaging AI evaluation platform | https://www.axios.com/pro/health-tech-deals/2026/11/16/testdynamics-series-a-9m

  4. [Business Wire, November 2026] TestDynamics Secures $9M in funding, with Series A Led by Healthier Capital, and Participation from Cedars-Sinai Technology Ventures | https://www.businesswire.com/news/home/20261116497451/en/TestDynamics-Secures-$9M-in-funding-with-Series-A-Led-by-Healthier-Capital-and-Participation-from-Cedars-Sinai-Technology-Ventures

  5. [FTS Podcast, October 2026] TestDynamics | https://www.ftspod.com/episodes/lior-eshel

  6. [TestDynamics] TestDynamics · We make imaging AI work. | https://testdynamics.net/

  7. [Business Wire, November 2025] TestDynamics Introduces Amalgamated Intelligence™ - The First Holistic Intelligence Framework That Unifies All Medical Imaging AI Into One Cohesive System | https://www.businesswire.com/news/home/20251120995693/en/TestDynamics-Introduces-Amalgamated-Intelligence-The-First-Holistic-Intelligence-Framework-That-Unifies-All-Medical-Imaging-AI-Into-One-Cohesive-System

  8. [Crunchbase] TestDynamics - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/testdynamics

Articles about TestDynamics

View on Startuply.vc